Menopausal Symptom Management in Breast Cancer Survivors — A Promising New Option
Mené sur 474 patientes atteintes d'un cancer du sein HR+ (âge : 18-70 ans), cet essai randomisé évalue l'efficacité de l'élinzanétant pour prévenir et traiter les symptômes vasomoteurs induits par un traitement endocrinien
Among women with a history of early breast cancer treated with endocrine therapy (tamoxifen or aromatase inhibitors), vasomotor symptoms are common, occurring in up to 90% of this population, and often severe.1 These symptoms are attributable to mainstay treatments used to reduce disease recurrence and improve survival. Two such treatments are chemotherapy, which causes temporary or permanent ovarian suppression and is associated with precipitously low levels of estradiol in premenopausal women, and endocrine therapy, which is used to decrease or block estrogen in breast cancer survivors of all ages. Menopausal symptoms not only affect quality of life among survivors of . . .
New England Journal of Medicine , éditorial, 2025